News Headlines Article

Skin cancer drug combo with Genentech sends Exelixis stock soaring
San Francisco Business Times

A combination of drugs from two South San Francisco biotech companies helped patients with an advanced skin cancer live longer without their disease worsening than if they took one of the drugs alone, according to early data from a clinical trial. The strong, albeit preliminary, results will push Genentech Inc. to seek Food and Drug Administration approval of the drug combo targeting deadly melanoma by the end of the year.